Review



human non small cell lung cancer cell lines h460  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 98
      Buy from Supplier

    Structured Review

    ATCC human non small cell lung cancer cell lines h460
    Human Non Small Cell Lung Cancer Cell Lines H460, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 2575 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+nci+h460+lung+cancer+cells/pm41596373-290-0-30?v=ATCC
    Average 98 stars, based on 2575 article reviews
    human non small cell lung cancer cell lines h460 - by Bioz Stars, 2026-07
    98/100 stars

    Images



    Similar Products

    human non small cell lung cancer cell lines h460  (ATCC)
    98
    ATCC human non small cell lung cancer cell lines h460
    Human Non Small Cell Lung Cancer Cell Lines H460, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+nci+h460+lung+cancer+cells/pm41596373-290-0-30?v=ATCC
    Average 98 stars, based on 1 article reviews
    human non small cell lung cancer cell lines h460 - by Bioz Stars, 2026-07
    98/100 stars
    		  Buy from Supplier
    human large cell lung cancer cell nci h460  (ATCC)
    98
    ATCC human large cell lung cancer cell nci h460
    nCoV-L induced cancer cell death in vitro and suppressed tumor growth in viv o (A) Schematic structure of the stem-loop-structured nCoV-L RNA agonist. (B, C) nCoV-L activated the RIG-I signalling in cancer cells. Hep3B (B) or Huh7 (C) cells were collected and subjected to Western blot analysis after treated with Lipo or Lipo mixed with 2 μg nCoV-L for 24 h. Protein levels of RIG-I, p-IRF3, STAT1, p-STAT1, p–NF–κb and ISG56 were compared to control and Lipo groups. (D) RIG-I signalling deficiency suppressed nCoV-L-induced cell death. Huh7.5.1 cells were transfected with 50 ng nCoV-L. Cell viability was measured 24 h post-transfection using a CCK-8 assay. Data represented mean ± SD; P < 0.05. (E) Ablation of 5ʹ-PPP abolishes nCoV-L-induced cell death. Hep3B cells were transfected with 200 ng of in vitro -transcribed nCoV-L RNA or 5ʹ-PPP-deficient synthetic nCoV-L RNA. Cell viability was quantified 24 h later by CCK-8 assay. Data represented mean ± SD; P < 0.0001. (F) Dose-dependent cytotoxicity of nCoV-L across carcinoma cell lines. Hep3B, <t>NCI–H460,</t> SW620, SW480, and CT26.WT cells were transfected with 50, 100, or 150 ng nCoV-L. Cell viability was assessed 48 h post-transfection using CCK-8 assay. (G) nCoV-L suppressed NCI–H1299 xenograft growth. Mice received intratumoral injections of PBS, lipo, or 10 μg nCoV-L complexed with lipo (nCoV-L/lipo) for 5 consecutive days (arrows, days 0–4). Tumor volumes are shown as mean ± SEM (n = 5); P < 0.0001 vs. PBS (two-way ANOVA). (H) Representative excised tumors from (G). Scale bar: 0.5 cm.
    Human Large Cell Lung Cancer Cell Nci H460, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+nci+h460+lung+cancer+cells/pmc12803795-25-7-25?v=ATCC
    Average 98 stars, based on 1 article reviews
    human large cell lung cancer cell nci h460 - by Bioz Stars, 2026-07
    98/100 stars
    		  Buy from Supplier
    nci h460 large cell human lung cancer cells  (ATCC)
    98
    ATCC nci h460 large cell human lung cancer cells
    nCoV-L induced cancer cell death in vitro and suppressed tumor growth in viv o (A) Schematic structure of the stem-loop-structured nCoV-L RNA agonist. (B, C) nCoV-L activated the RIG-I signalling in cancer cells. Hep3B (B) or Huh7 (C) cells were collected and subjected to Western blot analysis after treated with Lipo or Lipo mixed with 2 μg nCoV-L for 24 h. Protein levels of RIG-I, p-IRF3, STAT1, p-STAT1, p–NF–κb and ISG56 were compared to control and Lipo groups. (D) RIG-I signalling deficiency suppressed nCoV-L-induced cell death. Huh7.5.1 cells were transfected with 50 ng nCoV-L. Cell viability was measured 24 h post-transfection using a CCK-8 assay. Data represented mean ± SD; P < 0.05. (E) Ablation of 5ʹ-PPP abolishes nCoV-L-induced cell death. Hep3B cells were transfected with 200 ng of in vitro -transcribed nCoV-L RNA or 5ʹ-PPP-deficient synthetic nCoV-L RNA. Cell viability was quantified 24 h later by CCK-8 assay. Data represented mean ± SD; P < 0.0001. (F) Dose-dependent cytotoxicity of nCoV-L across carcinoma cell lines. Hep3B, <t>NCI–H460,</t> SW620, SW480, and CT26.WT cells were transfected with 50, 100, or 150 ng nCoV-L. Cell viability was assessed 48 h post-transfection using CCK-8 assay. (G) nCoV-L suppressed NCI–H1299 xenograft growth. Mice received intratumoral injections of PBS, lipo, or 10 μg nCoV-L complexed with lipo (nCoV-L/lipo) for 5 consecutive days (arrows, days 0–4). Tumor volumes are shown as mean ± SEM (n = 5); P < 0.0001 vs. PBS (two-way ANOVA). (H) Representative excised tumors from (G). Scale bar: 0.5 cm.
    Nci H460 Large Cell Human Lung Cancer Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+nci+h460+lung+cancer+cells/pmc12690519-39-0-10?v=ATCC
    Average 98 stars, based on 1 article reviews
    nci h460 large cell human lung cancer cells - by Bioz Stars, 2026-07
    98/100 stars
    		  Buy from Supplier
    human lung cancer cell line h460  (ATCC)
    98
    ATCC human lung cancer cell line h460
    nCoV-L induced cancer cell death in vitro and suppressed tumor growth in viv o (A) Schematic structure of the stem-loop-structured nCoV-L RNA agonist. (B, C) nCoV-L activated the RIG-I signalling in cancer cells. Hep3B (B) or Huh7 (C) cells were collected and subjected to Western blot analysis after treated with Lipo or Lipo mixed with 2 μg nCoV-L for 24 h. Protein levels of RIG-I, p-IRF3, STAT1, p-STAT1, p–NF–κb and ISG56 were compared to control and Lipo groups. (D) RIG-I signalling deficiency suppressed nCoV-L-induced cell death. Huh7.5.1 cells were transfected with 50 ng nCoV-L. Cell viability was measured 24 h post-transfection using a CCK-8 assay. Data represented mean ± SD; P < 0.05. (E) Ablation of 5ʹ-PPP abolishes nCoV-L-induced cell death. Hep3B cells were transfected with 200 ng of in vitro -transcribed nCoV-L RNA or 5ʹ-PPP-deficient synthetic nCoV-L RNA. Cell viability was quantified 24 h later by CCK-8 assay. Data represented mean ± SD; P < 0.0001. (F) Dose-dependent cytotoxicity of nCoV-L across carcinoma cell lines. Hep3B, <t>NCI–H460,</t> SW620, SW480, and CT26.WT cells were transfected with 50, 100, or 150 ng nCoV-L. Cell viability was assessed 48 h post-transfection using CCK-8 assay. (G) nCoV-L suppressed NCI–H1299 xenograft growth. Mice received intratumoral injections of PBS, lipo, or 10 μg nCoV-L complexed with lipo (nCoV-L/lipo) for 5 consecutive days (arrows, days 0–4). Tumor volumes are shown as mean ± SEM (n = 5); P < 0.0001 vs. PBS (two-way ANOVA). (H) Representative excised tumors from (G). Scale bar: 0.5 cm.
    Human Lung Cancer Cell Line H460, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+nci+h460+lung+cancer+cells/pm41260900-335-24-30?v=ATCC
    Average 98 stars, based on 1 article reviews
    human lung cancer cell line h460 - by Bioz Stars, 2026-07
    98/100 stars
    		  Buy from Supplier
    human lung cancer cell line nci h460  (ATCC)
    98
    ATCC human lung cancer cell line nci h460
    nCoV-L induced cancer cell death in vitro and suppressed tumor growth in viv o (A) Schematic structure of the stem-loop-structured nCoV-L RNA agonist. (B, C) nCoV-L activated the RIG-I signalling in cancer cells. Hep3B (B) or Huh7 (C) cells were collected and subjected to Western blot analysis after treated with Lipo or Lipo mixed with 2 μg nCoV-L for 24 h. Protein levels of RIG-I, p-IRF3, STAT1, p-STAT1, p–NF–κb and ISG56 were compared to control and Lipo groups. (D) RIG-I signalling deficiency suppressed nCoV-L-induced cell death. Huh7.5.1 cells were transfected with 50 ng nCoV-L. Cell viability was measured 24 h post-transfection using a CCK-8 assay. Data represented mean ± SD; P < 0.05. (E) Ablation of 5ʹ-PPP abolishes nCoV-L-induced cell death. Hep3B cells were transfected with 200 ng of in vitro -transcribed nCoV-L RNA or 5ʹ-PPP-deficient synthetic nCoV-L RNA. Cell viability was quantified 24 h later by CCK-8 assay. Data represented mean ± SD; P < 0.0001. (F) Dose-dependent cytotoxicity of nCoV-L across carcinoma cell lines. Hep3B, <t>NCI–H460,</t> SW620, SW480, and CT26.WT cells were transfected with 50, 100, or 150 ng nCoV-L. Cell viability was assessed 48 h post-transfection using CCK-8 assay. (G) nCoV-L suppressed NCI–H1299 xenograft growth. Mice received intratumoral injections of PBS, lipo, or 10 μg nCoV-L complexed with lipo (nCoV-L/lipo) for 5 consecutive days (arrows, days 0–4). Tumor volumes are shown as mean ± SEM (n = 5); P < 0.0001 vs. PBS (two-way ANOVA). (H) Representative excised tumors from (G). Scale bar: 0.5 cm.
    Human Lung Cancer Cell Line Nci H460, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+nci+h460+lung+cancer+cells/pmc12520770-41-0-38?v=ATCC
    Average 98 stars, based on 1 article reviews
    human lung cancer cell line nci h460 - by Bioz Stars, 2026-07
    98/100 stars
    		  Buy from Supplier
    human non small cell lung cancer cells nci h460  (ATCC)
    98
    ATCC human non small cell lung cancer cells nci h460
    nCoV-L induced cancer cell death in vitro and suppressed tumor growth in viv o (A) Schematic structure of the stem-loop-structured nCoV-L RNA agonist. (B, C) nCoV-L activated the RIG-I signalling in cancer cells. Hep3B (B) or Huh7 (C) cells were collected and subjected to Western blot analysis after treated with Lipo or Lipo mixed with 2 μg nCoV-L for 24 h. Protein levels of RIG-I, p-IRF3, STAT1, p-STAT1, p–NF–κb and ISG56 were compared to control and Lipo groups. (D) RIG-I signalling deficiency suppressed nCoV-L-induced cell death. Huh7.5.1 cells were transfected with 50 ng nCoV-L. Cell viability was measured 24 h post-transfection using a CCK-8 assay. Data represented mean ± SD; P < 0.05. (E) Ablation of 5ʹ-PPP abolishes nCoV-L-induced cell death. Hep3B cells were transfected with 200 ng of in vitro -transcribed nCoV-L RNA or 5ʹ-PPP-deficient synthetic nCoV-L RNA. Cell viability was quantified 24 h later by CCK-8 assay. Data represented mean ± SD; P < 0.0001. (F) Dose-dependent cytotoxicity of nCoV-L across carcinoma cell lines. Hep3B, <t>NCI–H460,</t> SW620, SW480, and CT26.WT cells were transfected with 50, 100, or 150 ng nCoV-L. Cell viability was assessed 48 h post-transfection using CCK-8 assay. (G) nCoV-L suppressed NCI–H1299 xenograft growth. Mice received intratumoral injections of PBS, lipo, or 10 μg nCoV-L complexed with lipo (nCoV-L/lipo) for 5 consecutive days (arrows, days 0–4). Tumor volumes are shown as mean ± SEM (n = 5); P < 0.0001 vs. PBS (two-way ANOVA). (H) Representative excised tumors from (G). Scale bar: 0.5 cm.
    Human Non Small Cell Lung Cancer Cells Nci H460, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+nci+h460+lung+cancer+cells/pm40818823-66-0-20?v=ATCC
    Average 98 stars, based on 1 article reviews
    human non small cell lung cancer cells nci h460 - by Bioz Stars, 2026-07
    98/100 stars
    		  Buy from Supplier

    Image Search Results


    nCoV-L induced cancer cell death in vitro and suppressed tumor growth in viv o (A) Schematic structure of the stem-loop-structured nCoV-L RNA agonist. (B, C) nCoV-L activated the RIG-I signalling in cancer cells. Hep3B (B) or Huh7 (C) cells were collected and subjected to Western blot analysis after treated with Lipo or Lipo mixed with 2 μg nCoV-L for 24 h. Protein levels of RIG-I, p-IRF3, STAT1, p-STAT1, p–NF–κb and ISG56 were compared to control and Lipo groups. (D) RIG-I signalling deficiency suppressed nCoV-L-induced cell death. Huh7.5.1 cells were transfected with 50 ng nCoV-L. Cell viability was measured 24 h post-transfection using a CCK-8 assay. Data represented mean ± SD; P < 0.05. (E) Ablation of 5ʹ-PPP abolishes nCoV-L-induced cell death. Hep3B cells were transfected with 200 ng of in vitro -transcribed nCoV-L RNA or 5ʹ-PPP-deficient synthetic nCoV-L RNA. Cell viability was quantified 24 h later by CCK-8 assay. Data represented mean ± SD; P < 0.0001. (F) Dose-dependent cytotoxicity of nCoV-L across carcinoma cell lines. Hep3B, NCI–H460, SW620, SW480, and CT26.WT cells were transfected with 50, 100, or 150 ng nCoV-L. Cell viability was assessed 48 h post-transfection using CCK-8 assay. (G) nCoV-L suppressed NCI–H1299 xenograft growth. Mice received intratumoral injections of PBS, lipo, or 10 μg nCoV-L complexed with lipo (nCoV-L/lipo) for 5 consecutive days (arrows, days 0–4). Tumor volumes are shown as mean ± SEM (n = 5); P < 0.0001 vs. PBS (two-way ANOVA). (H) Representative excised tumors from (G). Scale bar: 0.5 cm.

    Journal: Biochemistry and Biophysics Reports

    Article Title: Anti-tumor analysis of the RIG-I agonist in vitro and in vivo

    doi: 10.1016/j.bbrep.2025.102249

    Figure Lengend Snippet: nCoV-L induced cancer cell death in vitro and suppressed tumor growth in viv o (A) Schematic structure of the stem-loop-structured nCoV-L RNA agonist. (B, C) nCoV-L activated the RIG-I signalling in cancer cells. Hep3B (B) or Huh7 (C) cells were collected and subjected to Western blot analysis after treated with Lipo or Lipo mixed with 2 μg nCoV-L for 24 h. Protein levels of RIG-I, p-IRF3, STAT1, p-STAT1, p–NF–κb and ISG56 were compared to control and Lipo groups. (D) RIG-I signalling deficiency suppressed nCoV-L-induced cell death. Huh7.5.1 cells were transfected with 50 ng nCoV-L. Cell viability was measured 24 h post-transfection using a CCK-8 assay. Data represented mean ± SD; P < 0.05. (E) Ablation of 5ʹ-PPP abolishes nCoV-L-induced cell death. Hep3B cells were transfected with 200 ng of in vitro -transcribed nCoV-L RNA or 5ʹ-PPP-deficient synthetic nCoV-L RNA. Cell viability was quantified 24 h later by CCK-8 assay. Data represented mean ± SD; P < 0.0001. (F) Dose-dependent cytotoxicity of nCoV-L across carcinoma cell lines. Hep3B, NCI–H460, SW620, SW480, and CT26.WT cells were transfected with 50, 100, or 150 ng nCoV-L. Cell viability was assessed 48 h post-transfection using CCK-8 assay. (G) nCoV-L suppressed NCI–H1299 xenograft growth. Mice received intratumoral injections of PBS, lipo, or 10 μg nCoV-L complexed with lipo (nCoV-L/lipo) for 5 consecutive days (arrows, days 0–4). Tumor volumes are shown as mean ± SEM (n = 5); P < 0.0001 vs. PBS (two-way ANOVA). (H) Representative excised tumors from (G). Scale bar: 0.5 cm.

    Article Snippet: Mouse hepatocellular carcinoma (HCC) cells Hepa1-6, Hep3B, human large cell lung cancer cell NCI–H460, and non-small cell lung cancer cell (NSCLC) NCI–H1299 were purchased from ATCC.

    Techniques: In Vitro, Western Blot, Control, Transfection, CCK-8 Assay